ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VIR vs COAG // ENTERPRISE SCALE & MARKET CAP

Vir Biotechnology Inc. (NASDAQ) VS. Hemab Therapeutics Holdings Inc. (NASDAQ) • 15-METRIC TALLY: VIR 1 — COAG 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: VIR
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VIR VS. COAG) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VIR COAG SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -19.74% — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -7.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.40 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 — — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.8 67.2 -13.35 COAG /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $2.01B $1.89B $120.9M VIR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VIR REV COAG REV VIR GROSS % COAG GROSS % VIR FCF COAG FCF
FY 2025 $68.6M $0 98.0% — -$396.6M —
FY 2024 $74.2M — 98.0% — -$453.7M —
FY 2023 $86.2M — — — -$778.8M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VIR // BETA —
COAG // BETA —